Some observations on the effect of XXXX (micronized purified flavonoid fraction of Rutaceae aurantiae) in @entity3754 .

@entity1 @entity6567 @entity3754 @entity4 @entity23663
BACKGROUND: Morbidity management is a core component of the global programme for the elimination of @entity3754 . In a double-blind clinical trial, the tolerability and efficacy of @entity23663 (500 mg) + @entity6567 (25 mg) or DEC (25 mg) alone, twice daily for 90 days, was studied in 26 @entity1 with @entity3754 . RESULTS: None of the @entity1 in either drug group reported any adverse reaction throughout the treatment period (90 days). Haematological and biochemical parameters were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 90) values. The group receiving @entity23663 showed significant reduction in @entity4 volume from day 90 (140.6 PlusMinus; 18.8 ml) to day 360 (71.8 PlusMinus; 20.7 ml) compared to the pre-treatment (day 0, 198.4 PlusMinus; 16.5 ml) value. This accounted for a 63.8% reduction in @entity4 volume by day 360 (considering the pre-treatment (day 0) as 100%). In the DEC group, the changes in @entity4 volume (between day 1 and day 360) were not significant when compared to the pre-treatment (day 0) value. The percentage reduction at day 360 was only 9%, which was not significant (P > 0.05). CONCLUSION: This study has shown that @entity23663 (500 mg, twice a day for 90 days) is both safe and efficacious in reducing @entity4 volume in @entity3754 . Further clinical trials are essential for strengthening the evidence base on the role of this drug in the morbidity management of @entity3754 .
